Rescue Medication

Phase 2

Rescue Medication is one of 157 therapeutic programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[2][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Colorectal CancerRecruiting

Bladder CancerRecruiting

Non Muscle Invasive Bladder CancerRecruiting

Malignant NeoplasmRecruiting

Oesophageal Squamous Cell CarcinomaRecruiting

Castration Resistant Prostatic CancerRecruiting

Ovarian Cancer RecurrentRecruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Colorectal CancerPreclinical

Recruiting

Bladder CancerPreclinical

Recruiting

Non Muscle Invasive Bladder CancerPreclinical

Recruiting

Malignant NeoplasmPhase 2

Recruiting

Oesophageal Squamous Cell CarcinomaPreclinical

Recruiting

Castration Resistant Prostatic CancerPreclinical

Recruiting

Ovarian Cancer RecurrentPreclinical

Recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

25 2

Beyfortus

BeiGene

Phase 3

17 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

38 4

Tecentriq

Roche

Phase 3

6 5

Decadron

AAspen Global Incorporated

Phase 3

7 6

Mitosol

UUroGen Pharma Ltd.

Phase 3

1 7

Botensilimab

AAgenus Inc.

Phase 3

9 8

Cytokine-Induced Killer Cells

TThe First People's Hospital of Changzhou

Phase 3

2 9

Iron Isomaltoside

TThomas Jefferson University

Phase 3

3 10

Mfolfoxiri

DDominik Paul Modest

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Pain Management

NCT07862595

Q2 2028

PreclinicalRecruiting

Oesophageal Squamous Cell Carcinoma

NCT07405151

Q1 2029

PreclinicalRecruiting

Non Muscle Invasive Bladder Cancer

NCT06637423

Q4 2029

PreclinicalRecruiting

Colorectal Cancer

NCT06428409

Clinical

Trials by Indication[1]

Breast Neoplasms2 trials

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07060807·1,000 enrolled

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

MK-2870-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2870-U01 Master Protocol to Evaluate the Safety and Efficacy of Sacituzumab Tirumotecan (Sac-TMT; MK-2870) Alone or in Combination for the Treatment of Participants With Metastatic Castration-Resistant Prostate Cancer/Androgen Pathway Modulator Refractory (mCRPC/APMR)

Not yet recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07908524·290 enrolled

Prostate Cancer1 trial

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06925737·1,440 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·605 enrolled

13 more indications

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06841354·1,000 enrolled

Castration Resistant Prostatic Cancer1 trial

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06863272·360 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

Pain Management1 trial

A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Analgesic Effects and Safety of MK-6916 for Acute Pain Following Bunionectomy

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07862595·380 enrolled

Bladder Cancer1 trial

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07232602·55 enrolled

Oesophageal Squamous Cell Carcinoma1 trial

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07405151·60 enrolled

Malignant Neoplasm1 trial

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07252739·140 enrolled

Unspecified1 trial

A Clinical Study to Evaluate the Plasma Pharmacokinetics of a Single Dose of MK-4082 With and Without Diltiazem Coadministration in Healthy Participants

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT07697625·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Rescue Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rescue Medication. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Merck & Co.

Rescue Medication

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q1 2029

Q4 2029

Trials by Indication[1]

Breast Neoplasms2 trials

Lymphoma, Large B-Cell, Diffuse1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

Prostate Cancer1 trial

Ovarian Cancer Recurrent1 trial

Colorectal Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Non Muscle Invasive Bladder Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Triple Negative Breast Neoplasms1 trial

Castration Resistant Prostatic Cancer1 trial

Lung Neoplasm1 trial

Pain Management1 trial

Bladder Cancer1 trial

Oesophageal Squamous Cell Carcinoma1 trial

Malignant Neoplasm1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News